Lost in Translation: Revisiting the use of Tyrosine Kinase inhibitors in Colorectal Cancer

Colorectal cancer (CRC) is the 4th most lethal cancer in the world approximately causing 900,000 deaths every year. Recent advances in treatment options including surgery, radiotherapy, chemotherapy, and targeted therapy —along with early diagnosis—have improved the overall survival (OS) rate of patients with CRC [1]. In the cases of metastatic disease, fluoropyrimidine with either oxaliplatin and/or irinotecan (FOLFOXIRI/FOLFOX/FOLFIRI), often combined with bevacizumab or epidermal growth receptor (EGFR; cetuxi mab or panitumumab) are used as first-line chemotherapy regimens [2,3].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Laboratory-Clinic Interface Source Type: research